Cytek (CTKB) CEO Jiang Wenbin Receives 120,095 Shares via RSU Vesting

What Happened

• Jiang Wenbin, President & CEO and a director of Cytek Biosciences (CTKB), had multiple Restricted Stock Units (RSUs convert/vest) on August 18, 2026, resulting in the acquisition/conversion of 120,095 shares. To satisfy tax withholding, 36,269 of those shares were withheld (disposed) at $4.67 per share, totaling $169,377. The net shares issued to him were 83,826.
• The filings show conversion/settlement of RSU awards (transaction code M) and share-withholding to cover tax liabilities (code F). The derivative conversion entries report $0 value because they reflect conversion of RSUs into common stock.

Key Details

• Transaction date: August 18, 2026; Form 4 filed August 20, 2026 (filed within the typical 2-business-day window).
• Shares acquired via conversion: 120,095 total (11,781 + 22,100 + 29,002 + 57,212).
• Shares withheld for taxes: 36,269 shares at $4.67 each = $169,377 total.
• Net shares received: 83,826.
• Footnotes: These transactions relate to multiple RSU awards (each RSU = right to one share). Vesting schedules are staggered over four years (see footnotes F1–F6); F2 confirms the withheld shares were surrendered to cover tax withholding on Aug 18, 2026.
• Shares owned after the transaction: not specified in the supplied filing excerpt.

Context

• This is a routine RSU vesting and tax-withholding event (not an open-market sale or purchase). For RSU settlements, some shares are commonly withheld to satisfy tax obligations; this does not necessarily indicate a buy/sell signal by the insider.
• Transaction codes: M = conversion/exercise of a derivative (here, RSU vesting/settlement); F = share withholding/payment of tax liability.